Abstract Number: 0249 • ACR Convergence 2025
Obesity as a possible confusion factor in the scleroderma pattern
Background/Purpose: The 2023 EULAR criteria for systemic sclerosis reaffirm the diagnostic value of nailfold videocapillaroscopy (NVC), particularly the presence of giant capillaries and capillary loss…Abstract Number: 2377 • ACR Convergence 2025
Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of mortality among patients with systemic lupus erythematosus (SLE). Statin medications play a crucial role for…Abstract Number: 1913 • ACR Convergence 2025
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for autoimmune diseases but carries a risk of antimalarial-induced cardiomyopathy (AMIC) that increases with long-term use and is often…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…Abstract Number: 0820 • ACR Convergence 2025
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…Abstract Number: 0242 • ACR Convergence 2025
Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease (mediated by IL-1) that requires long-term treatment, and selection of therapy is guided by multiple factors.…Abstract Number: 2681 • ACR Convergence 2025
Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
Background/Purpose: Total cholesterol (TC) and low-density lipoprotein (LDL) are critical measures of atherosclerotic cardiovascular disease (ASCVD) risk. However, the lipid paradox in RA, whereby systemic…Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…Abstract Number: 1892 • ACR Convergence 2025
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention…Abstract Number: 1484 • ACR Convergence 2025
Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
Background/Purpose: Patients with autoimmune connective tissue disease, such as Systemic Lupus Erythematosus (SLE), are at higher risk for developing aortic valve pathology. However, the impact…Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 38
- Next Page »